Erratum: High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data (Epidemiology (2009) 20 (512-522) DOI: 10.1097/EDE.0b013e3181a663cc);High-dimensional propensity score adjustment in studies of treatment effects using health care claims data

Epidemiology

Volumn 20, Issue 4, 2009, Pages 512-522

  Schneeweiss, Sebastian ^a,b   Rassen, Jeremy A ^a   Glynn, Robert J ^a   Avorn, Jerry ^a   Mogun, Helen ^a   Brookhart, M Alan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ALGORITHM; ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL TOXICITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HIP FRACTURE; HUMAN; INFLUENZA VACCINATION; MEDICARE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STOMACH PROTECTION;

EID: 67651042983     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000886     Document Type: Erratum

References (40)

1. Arana A, Rivero E, Egberts TC. What do we show and who does so? An analysis of the abstracts presented at the 19th ICPE. Pharmacoepidemiol Drug Saf. 2004;13:S330-S331.
2. Schneeweiss S, Avorn J. Using health care utilization databases for epide-miologic research on therapeutics. J Clin Epidemiol. 2005;58:323-337.
3. Strom BL, Carson JL. Use of automated databases for pharmacoepide-miology research. Epidemiol Rev. 1990;12:87-107.
4. Walker AM. Confounding by indication. Epidemiology. 1996;7:335-336.
5. Schneeweiss S. Understanding secondary databases: a commentary on "Sources of bias for health state characteristics in secondary databases." J Clin Epidemiol. 2007;60:648-650.
6. Anderson RM. Revisiting the behavioral model and access to medical care: Does it matter? J Health Soc Behav. 1995;36:1-10.
7. Schneeweiss S, Glynn RJ, Avorn J, Solomon DH. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005;58:98-102.
8. Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43:951-959.
9. Wooldridge JM. Econometric Analysis ofCross Section and Panel Data.Cambridge, MA: MIT Press; 2001.
10. Greenland S. The effect of misclassification in the presence of covariates. Am J Epidemiol. 1980;112:564-569.
11. Greenland S, Robins JM. Confounding and misclassification. Am J Epidemiol. 1985;122:495-506.
12. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. PharmacoepidemiolDrugSaf. 2005;14:465-476.
13. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators ofstatin therapy. Pharmacoepidemiol DrugSaf. 2006;15:444-453.
14. Seeger JD, Kurth T, Walker AM. Use of propensity score technique to account for exposure-related covariates: an example and lesson. Med Care. 2007;45(suppl 2):S143-S148.
15. Deleted in proof.Hirano K, Imbens GW. Estimation of causal effects using propensity score weighting: An application to data on right heart catheterization. Health Serv Outcomes Res Methodol. 2001;2:259-278.
16. Judkins DR, Morganstein D, Zador P, Piesse A, Barrett B, Mukhopadhyay P. Variable selection and ranking in propensity scoring. Stat Med. 2007;26:1022-1033.
17. Van der Laan M, Robins JM. Unified Methods for Censored Longitudinal Data and Causality. New York: Springer; 2003.
18. Robins JM, Mark SD, Newey WK. Estimating exposure effects by modelling the expectation of exposure conditional on confounders.Biometrics. 1992;48:479-495.
19. Brookhart MA, Schneeweiss S, Rothman K, Glynn RJ, Avorn J, Sturmer T. Variable selection in propensity score models. Am J Epidemiol. 2006;163:1149-1156.
20. Greenland S. Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology. 2003;14:300-306.
21. Schneeweiss S, Patrick AR, Sturmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45:S131-S142.
22. Bross ID. Spurious effects from an extraneous variable. JChronic Dis.1966;19:637- 647.
23. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59:437-447.
24. Solomon DH, Schneeweiss S, Glynn RJ, et al. The relationship between selective COX-2 inhibitors and acute myocardial infarction. Circulation. 2004;109:2068-2073.
25. McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: The Oregon experience. J Clin Epidemiol. 2000;53:1248-1257.
26. West S, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self report compared with database information. Am JEpidemiol. 1995;142:1103-1112.
27. Ray W. Evaluating medication effects outside ofclinical trials: new-user designs. Am JEpidemiol. 2003;158:915-920.
28. Raiford DS, Perez Gutthann S, Garcia Rodriguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology. 1996;7:101-104.
29. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7:R644-R665.
30. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000;160:2998-3003.
31. Eisen GM, Goldstein JL, Hanna DB, Rublee DA. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Aliment Pharmacol Ther. 2005;21:591-598.
32. Schneeweiss S, Solomon DH, Wang PS, Brookhart MA. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective COX-2 inhibitors and non-selective NSAIDs: an instrumental variable analysis. Arthritis Rheum. 2006;54:3390-3398.
33. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. JGerontol A Biol Sci Med Sci. 2007;62:879-887.
34. Glynn RJ, Schneeweiss S, Wang P, Levin R, Avorn J. Selective prescribing can lead to over-estimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006;59:819-828.
35. Greenland S. Invited commentary: Variable selection versus shrinkage in the control ofmultiple confounders. Am JEpidemiol. 2008;167:523-529.
36. Lefebrve G, Delaney JA, Platt RW. Impact of mis-specification of the treatment model on estimates from a marginal structural model. Stat Med. 2008;27:3629-3642.
37. Fu AZ, Li L. Thinking of having a higher predictive power for your first-stage model in propensity score analysis? Think again. Health Serv Outcomes Res Methodol. 2008;8:115-117.
38. Freedman DA, Navidi W, Peters SC. On the impact of variable selection in fitting regression equations. In: DijlestraTK, ed. On Model Uncertainty and its Statistical Implications. Berlin, Germany: Springer; 1988:1-16.
39. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, and what? Stat Med. 2000;19:1141-1164.
40. van der Laan MJ, Dudoit S. Unified Cross-Validation Methodology For Selection Among Estimators and a General Crossvalidated Adaptive Epsi-lon-Net Estimator: Finite Sample Oracle Inequalities And Examples. Berkeley, CA: Division of Biostatistics, University of California, Berkeley; 2003. UC Berkeley Division of Biostatistics Working Paper Series, paper 130. (Available at: http://www.bepress.com/ucbbiostat/paper130).Brookhart MA, van der Laan MJ. A semiparametric model selection criterion with applications to the marginal structural model. Comput Stat Data Anal. 2006;50:475-498.